IL22 and Cowden disease: In clinical trials evaluating the efficacy of risankizumab and brazikumab, two monoclonal antibodies targeting the IL-23 p19 subunit in individuals with moderately-to-severely active CD, IL-22 plasma concentrations were assessed.